This editorial refers to 'Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drugeluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome' † , by S. Saito et al., on page 2460.
DES was proved to be superior to BMS in pivotal randomized trials (Table 1) . 4, 5 BMS significantly reduces the risk of abrupt closure and early restenosis as compared to balloon angioplasty; early generation DES with anti-proliferative drugs further reduces early in-stent restenosis and current generation DES has substantially reduced very late stent thrombosis. In the DES era, PCI has indeed matured into a safe and effective revascularization procedure with excellent clinical outcomes, at least up to 5 years; 6, 7 thus, newer coronary DES have been evaluated by randomized controlled trials testing their non-inferiority, instead of superiority, to their control devices ( Table 1) . As delayed endothelialization after DES implantation could be a potential substrate of adverse events such as stent thrombosis, 8 bone marrow-derived CD34 þ endothelial progenitor cells (EPCs) capture stents have been developed, which aim to achieve early healing following stent placement. 9 Anti-CD34 antibodies coated on the surface of struts capture EPCs, which differentiate into endothelial cells facilitating endothelial coverage of the stent. While the original EPC capture stent without drug elution failed to show non-inferiority to DES with regard to target lesion failure, 10 a COMBO dual-therapy stent has been introduced that offers sirolimus elution to prevent restenosis, as well as technology to capture circulating EPCs to accelerate healing. The concept of the COMBO dual-therapy stent is still under evaluation in real-world clinical studies. The REMEDEE (Randomized study to Evaluate the safety and effectiveness of an abluMinal sirolimus coatED bio-Engineered stEnt) study showed the non-inferiority of the COMBO stent (0.39 ± 0.45 mm) with regard to in-stent late lumen loss compared with a first-generation paclitaxel-eluting stent (0.44 ± 0.56 mm), 11 while the REMEDEE-OCT (Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS patients by Means of OCT) study showed a significantly higher per cent of uncovered struts per stent at 60 days in lesions treated with the COMBO stent (14.7%) compared with the current standard DES of everolimus-eluting stent (EES) (7.7%, P = 0.04). 12 In this issue of the European Heart Journal, Saito et al. report the primary results of a randomized comparison between the COMBO stent vs. EES in the Japan-USA HARMONEE study. 13 The study was designated to test the non-inferiority of COMBO stent to EES with a relatively large absolute non-inferiority margin of 7% based on the imputed effect of an ineffective treatment (BMS) for the assumed a 1-year target vessel failure (TVF) rate of 9% in the EES arm ( Table 1) . The COMBO stent fulfilled the prespecified non-inferiority criteria at P=0.02 with a 1-year TVF rate of 7.0% as compared with 4.2% in EES. However, the observed 1-year TVF rate of 4.2% in the EES arm was much lower than the assumed rate of 9%, leading to the unacceptably large non-inferiority margin (2.67 on the hazard ratio scale). In the OCT substudy (COMBO n = 69 and EES n = 64), a significantly greater amount of strut coverage (>40 lm) was observed at 1 year in the COMBO arm (91.6%) as compared with the EES arm (74.8%, P < 0.001), whereas it is of note that almost all struts were covered (99. NA, not applicable; MI, myocardial infarction; CABG, coronary artery bypass grafting; TLR, target lesion revascularization; LLL, late lumen loss; ID-TLR, ischaemia-driven target lesion revascularization; ID-TVR, ischaemia-driven target vessel revascularization; BMS, bare metal stent; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES, zotarolimus-eluting stent; DP-EES, durable polymer everolimus-eluting stent; BP-BES, biodegradable polymer biolimus-A9 eluting stent;
PrCr-EES, platinum-chromium everolimus-eluting stent; BP-PrCr-EES, biodegradable polymer platinum-chromium everolimus-eluting stent; BP-SES, biodegradable polymer sirolimus-eluting stent; RES, ridaforolimus-eluting stent; BVS, bioresorbable vascular scaffold; EPC, endothelial progenitor cells; POCE, patient oriented composite endpoint (all-cause death, any myocardial infarction or any revascularization); DOCE, device oriented composite endpoint (cardiac death, target vessel-related myocardial infarction, and ischaemia-driven target lesion revascularization); TLF, target lesion failure (cardiac death, target vessel-related myocardial infarction, and any ischaemia-driven target lesion revascularization); TVF, target vessel failure (cardiac death, any myocardial infarction, ischaemia-driven target vessel revascularization). together, it would be hard to accept the 'non-inferiority' of the COMBO dual-therapy stent as compared to EES. In some pivotal Japanese studies, including the Japan-USA HARMONEE study, a large non-inferiority margin was pre-specified on the basis of a previous randomized superiority trial comparing DES and BMS to prove that we do not step back to the BMS era. 13, 14 Furthermore, the assumed event rate in the control group was often overestimated ( Table 1) . More than 18 years have already passed since the first DES was implanted in a human; almost half of the history of PCI. 15 During these two decades, we have already accumulated sufficient evidence regarding the benefits of early and current generation DES. It is high time that we believe that we have already moved forward two steps beyond BMS and one step beyond early generation DES. Therefore, pivotal studies of newer coronary devices should be designed to allow the confirmation of real noninferiority of current generation DES with reasonable non-inferiority margins that are not based on the imputed effect of BMS.
